LG Chem's Out-Licensed Gout Drug Enters Phase 3 Clinical Trial in China
Innovent Begins Dosing Patients in Phase 3 Trial of Tigulixostat
LG Chem announced on March 23 that Innovent Biologics, which holds the license for its novel gout drug candidate Tigulixostat in China, has begun dosing the first patient in a Phase 3 clinical trial in China.
In this Phase 3 trial, Innovent plans to enroll 600 gout patients and conduct a comparative assessment against febuxostat, an existing uric acid-lowering agent. The company will analyze the percentage of patients achieving target serum uric acid levels at week 24, as well as the long-term safety profile over one year of continued use.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Since its establishment in 2011, Innovent has experienced rapid growth through the development and commercialization of novel therapies for cancer and immune diseases. The company is now actively seeking to enter the gout market by adding new drug development programs, including treatments for acute gout flares.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.